Similarly, use of C6 home medications was also the only variable associated with an increased probability of XDDI involving SOFcontaining therapy (OR 3.83, 95% CI 2.57-5.70,
p\0.001).
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INTRODUCTION
Several new medications have become available to treat chronic hepatitis C (HCV) infection.
These include drugs from several new directacting antiviral medication classes that are inhibitors of non-structural (NS)3/4A serine protease and NS5B polymerase [1, 2] . The treatment of chronic HCV infection has become more widely available given the approval of these medications. The clinical guidance for treating chronic HCV infection now typically includes multiple drugs: sofosbuvir (SOF) or simeprevir (SIM) in combination with other medications [3] . The simultaneous use of multiple medications, polypharmacy, is associated with an increased likelihood of contraindicated drug-drug interactions (XDDI) [4] .
Important safety concerns arise when dealing with polypharmacy due to the increased potential of XDDIs among the chronic HCV-infected population. The majority of patients with chronic hepatitis C are between the ages of 50-70 years and, as such, typically have developed age-related comorbidities that often necessitate management with chronic maintenance medications [5, 6] . Some of these medications may interact with HCV therapy and could potentially result in poor treatment outcomes including toxicity and incomplete therapy, which may lead to a diminished probability of achieving a sustained virologic response, or the development of resistance [7, 8] Revision (ICD-9) codes related to hepatitis C infection: 070.41 (acute hepatitis C with hepatic coma), 070.44 (chronic hepatitis C with hepatic coma), 070.51 (acute hepatitis C without mention of hepatic coma), 070.54
(chronic hepatitis C without mention of hepatic coma), 070.70 (unspecified hepatitis C without hepatic coma), and 070.71 (unspecified hepatitis C with hepatic coma). Each of these patients was screened to confirm HCV infection and for the following inclusion criteria: (1) age C18 years, (2) laboratory-confirmed HCV infection, and (3) availability of a medication list. Patients with (HIV) were excluded because of the strong influence of antiretroviral therapy on the probability of XDDIs [11] . 
RESULTS
There were 4,251 patients who met inclusion criteria. The mean ± standard deviation (SD) age was 59.8 ± 7.6 years. The majority (n = 4,102, 96.5%) of patients were male.
Caucasian race (n = 2,476, 58.2%) was observed most frequently, followed by African American (n = 1,219, 28.7%), other (n = 438, 10.3%), and Hispanic (n = 118, 2.8%). The median (interquartile range, IQR) number of years since HCV diagnosis was 12 (8) (9) (10) (11) (12) (13) (14) . The median (IQR) numbers of comorbidities and home medications used were 7 (5-10) and 7 (4-11), respectively. There were 477 (11.2%) patients with cirrhosis.
The prevalence of XDDI before the addition of SIM-or SOF-containing therapy was 16.7% (n = 709). After the addition of SIM-and SOFcontaining therapy, the overall prevalence of XDDIs significantly increased to 25.9% (n = 1,103) and 19.9% (n = 844, p\0.001), respectively. When restricting interactions to only those involving SIM-or SOF-containing therapy ( Fig. 1) , the prevalence of XDDIs after the addition of these drugs was 12.6% (n = 535) and 4.7% (n = 201, p\0.001) for SIM-and SOFcontaining therapies, respectively. Upon stratification by the CART-derived breakpoints (\ or C6 home medications and having \ or C10 comorbidities), there were significant differences in the frequency of XDDIs involving HCV therapy between SIM-and SOF-containing regimens. The differences within each of the strata were consistent with the overall comparison in that SIM-containing drugs tended to be associated with a greater likelihood of an XDDI.
The bivariate analyses of XDDIs involving HCV medications after the addition of SIM-and SOF-containing therapies are described in Table 1 Fewer variables were significantly associated with XDDI involving SOF-containing therapy.
These included age, total number of home medications, antipsychotics, antidepressants, antiepileptic drugs, CNS depressants, corticosteroids, alpha or muscarinic-3 blocker, total number of comorbidities, bipolar/mood/ personality disorder, depression, seizure disorder, post-traumatic stress disorder, neuropathy, and cirrhosis. The use of C6 home medications and having C10 comorbidities was associated with an increased frequency of XDDI involving either SIM-or SOF-containing therapy.
In multivariable analyses examining the predictors of XDDIs involving SIM-containing therapy, the only medication-related predictor was use of C6 home medications (odds ratio OR 4.58, 95% confidence interval CI 3.54-5.20, p\0.001). Similarly, the use of C6 home medications was also the only variable associated with an increased probability of XDDI involving SOF-containing therapy (OR 3.83, 95% CI 2.57-5.70, p\0.001). To make the models more specific, the use of C6 home medications was replaced with the medication classes associated with XDDI involving either SIM-or SOF-containing therapy. The results of these refined multivariable models are displayed in 
DISCUSSION
Therapies containing SIM or SOF are associated with a high cost and it is imperative that clinicians take appropriate measures to ensure that patients have the highest likelihood of completing therapy, achieving a sustained virologic response and minimizing adverse events [13] . In some situations, adverse events that are a function of XDDIs can be prevented by proactively identifying patients at risk for XDDIs prior to prescribing SIM or SOFcontaining therapy and choosing the type of therapy that is associated with a lower probability or using them in patients who do not have risk factors for XDDIs [14] . This intervention, coupled with optimal drug adherence, can contribute to the probability of a good treatment outcome.
The majority of other population-based drug-drug interaction studies have been focused on patients with HIV/HCV coinfection [9, 10] . The present study, one of the largest population-based drug-drug interaction studies, focused on patients with HCV monoinfection. Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
